

Target	
<b>Mechanism of Action</b>	<ul style="list-style-type: none"> <li>GSPT1 degradation</li> </ul>
<b>Indication - Primary</b>	<ul style="list-style-type: none"> <li>Lymphoma and leukemia</li> </ul>
<b>Indication - Expansion</b>	<ul style="list-style-type: none"> <li>Antitumor agent</li> </ul>
<b>Route of Administration</b>	<ul style="list-style-type: none"> <li>PO</li> </ul>
<b>Competitive Advantage</b>	<ul style="list-style-type: none"> <li>Novel structure</li> </ul>
<b>Data Files</b>	<ul style="list-style-type: none"> <li>GSPT1 degradation in cells</li> <li>Cytotoxicity data against lymphoma and leukemia cell lines</li> <li>PK data</li> <li>On going in vivo efficacy study</li> </ul>
<b>IP Status</b>	<ul style="list-style-type: none"> <li>Patent filing</li> </ul>
<b>Collaboration Model</b>	<ul style="list-style-type: none"> <li>Collaborative research followed by licensing out</li> </ul>
<b>Contact (Science)</b>	<ul style="list-style-type: none"> <li>Jae Du Ha (jdha@krict.re.kr, +82-42-860-7072)</li> <li>Jong Yeon Hwang (jyhwang@krict.re.kr, +82-42-860-7045)</li> </ul>
<b>Contact (Licensing)</b>	<ul style="list-style-type: none"> <li>Moon Geun Jung (Technology marketing office, mgjung@krict.re.kr, +82-42-860-7746)</li> <li>Choon-gil Kim (Technology marketing office, joykim@krict.re.kr, +82-42-860-7079)</li> <li>Kyung Sun Choi (Technology marketing office, chanian@krict.re.kr, +82-42-860-7076)</li> </ul>